Becton, Dickinson and Company $BDX Shares Sold by Waverly Advisors LLC

Key Points

• Waverly Advisors cut its Becton, Dickinson and Company stake by 54.8% in the second quarter, selling 9,668 shares and retaining 7,972 shares valued at approximately $1.2 million. Institutional investors collectively own 86.97% of BDX.
• BD reported quarterly earnings of $3.23 per share and revenue of $4.98 billion, exceeding analyst expectations, while revenue increased 5.4% year over year. The company reaffirmed fiscal 2026 EPS guidance of $12.62–$12.72.
• The company declared a quarterly dividend of $1.05 per share, equivalent to a 2.4% annualized yield, while analyst sentiment remains mixed with a consensus “Hold” rating and an average price target of $187.67.

Waverly Advisors LLC trimmed its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 54.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,972 shares of the medical instruments supplier's stock after selling 9,668 shares during the quarter. Waverly Advisors LLC's holdings in Becton, Dickinson and Company were worth $1,206,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of BDX. Imprint Wealth LLC purchased a new position in Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. SHP Wealth Management purchased a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at $26,000. Meeder Asset Management Inc. increased its stake in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 102 shares during the period. Main Street Group LTD purchased a new position in shares of Becton, Dickinson and Company during the first quarter worth $29,000. Finally, Bell Investment Advisors Inc acquired a new position in Becton, Dickinson and Company during the second quarter valued at $29,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Trading Down 0.0%

Shares of Becton, Dickinson and Company stock opened at $177.85 on Monday. The firm has a 50-day simple moving average of $172.51 and a two-hundred day simple moving average of $160.48. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The company has a market cap of $49.00 billion, a P/E ratio of 53.57, a price-to-earnings-growth ratio of 12.53 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company's quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. Becton, Dickinson and Company's payout ratio is 126.51%.

Insiders Place Their Bets

In related news, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares of the company's stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 8,005 shares of company stock valued at $1,423,580. Corporate insiders own 0.40% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on BDX shares. Bank of America increased their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Monday, August 31st. UBS Group started coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a "buy" rating and a $190.00 price objective for the company. Weiss Ratings restated a "sell (d+)" rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Evercore set a $180.00 target price on Becton, Dickinson and Company in a report on Monday, July 6th. Finally, Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $187.67.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD's products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.